AbbVie, Alvotech Pact Means Humira Copy Can Launch in July 2023

AbbVie Inc. and Alvotech Holdings SA said they’ve settled all U.S. litigation involving Humira, granting Alvotech a nonexclusive license to sell its cheaper generic version of the arthritis treatment starting in July 2023.

The agreement, which the companies announced on Tuesday in separate press releases, ends AbbVie’s and Alvotech’s patent-infringement disputes pending at the U.S. International Trade Commission and in Illinois federal court, and a trade-secrets case that was dismissed by a federal judge in Chicago but was on appeal.

The ITC announced in January that it had launched an investigation based on a complaint AbbVie filed seeking to block ...